Research ArticleBasic Science Investigations
Dual-Receptor–Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates
Eva J. Razumienko, Jason C. Chen, Zhongli Cai, Conrad Chan and Raymond M. Reilly
Journal of Nuclear Medicine March 2016, 57 (3) 444-452; DOI: https://doi.org/10.2967/jnumed.115.162339
Eva J. Razumienko
1Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, Canada
Jason C. Chen
1Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, Canada
Zhongli Cai
1Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, Canada
Conrad Chan
1Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, Canada
Raymond M. Reilly
1Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, Canada
2Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada
3Toronto General Research Institute, Toronto, Ontario, Canada; and
4Joint Department of Medical Imaging, University Health Network, Toronto, Ontario, Canada

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 57, Issue 3
March 1, 2016
Dual-Receptor–Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates
Eva J. Razumienko, Jason C. Chen, Zhongli Cai, Conrad Chan, Raymond M. Reilly
Journal of Nuclear Medicine Mar 2016, 57 (3) 444-452; DOI: 10.2967/jnumed.115.162339
Dual-Receptor–Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates
Eva J. Razumienko, Jason C. Chen, Zhongli Cai, Conrad Chan, Raymond M. Reilly
Journal of Nuclear Medicine Mar 2016, 57 (3) 444-452; DOI: 10.2967/jnumed.115.162339